Superworth

ANI Pharmaceuticals price to free cash flow ANIP

Market value divided by free cash flow over the last twelve months, since 2014.

Today, Oct 23, 2026
9.6×
10-year median
16.4×
Against its 10-year history
6th
percentile: 0 is its lowest day, 100 its highest
10-year range
7.2× to 118×
Peer median
7.8×

ANI Pharmaceuticals' price to free cash flow is 9.6× as of Oct 23, 2026.

That is below its ten-year median of 16.4×, lower than on 94% of days in the last ten years.

Over that time it ranged from 7.2× in Oct 2020 to 118× in Dec 2021.

The median for 10 large drugmakers of a similar size is 7.8×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far9.6×9.2×12.2×
202511.9×11.5×33.2×
202414.9×11.7×20.3×
202318.8×16.6×43.1×
202284.4×84.3×102×
2021107×14.4×118×
202017.9×7.2×19.2×
201911.9×10.8×19.5×
201811.0×10.3×30.8×
201727.4×23.2×54.8×
201644.4×15.2×46.4×
201523.7×22.3×102×
201481.1×79.3×236×

Against its peers

Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first, today.

CompanyPrice to free cash flow
ANIPANI Pharmaceuticals9.6×
PAHCPhibro Animal Health160×
ANABAnaptysbion/m
PCRXPacira BioSciences8.1×
HRMYHarmony Biosciencesn/m
PBHPrestige Consumer Healthcare9.6×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals7.0×
NRIXNurix Therapeutics7.5×
ABUSArbutus Biopharman/m
OGNOrganon6.4×
Peer median7.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on ANI Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.